
From the title of my last article on this matter - "No Defense for the OTAs" – it would be easy to depict my adamant stance on this critical issue as one of hellfire and brimstone. Rest assured though, I didn't settle on this overnight. And judging from the comments I have received, many seem to agree. In fact, of the numerous and detailed responses from industry members, not one has genuinely argued in favor of the OTAs. On the contrary, some individuals have even harkened their utilization to that of a mainline drug.
More